Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
ESMO 2021 Roundup
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2021 Roundup ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
22 Sep 2021
PARP inhibitors in prostate cancer: Case based testing and clinical decisions
Dr Neal Shore and Prof Fred Saad
PARP inhibitors in prostate cancer: Case based testing and clinical decisions ( Dr Neal Shore and Prof Fred Saad )
20 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 4
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 4 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
20 Sep 2021
Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduct...
Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduction in risk of death compared to ADT + docetaxel alone in prostate cancer ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )
19 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 3
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
19 Sep 2021
STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic r...
Prof Janet Brown - University of Sheffield, Sheffield, United Kingdom
STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic renal cancer ( Prof Janet Brown - University of Sheffield, Sheffield, United Kingdom )
19 Sep 2021
Nivolumab with alternatively scheduled ipilimumab in first-line treatment of adv...
Dr Naveen Vasudev - Leeds Cancer Centre, Leeds, UK
Nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced RCC ( Dr Naveen Vasudev - Leeds Cancer Centre, Leeds, UK )
19 Sep 2021
High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advan...
Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands
High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer ( Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands )
18 Sep 2021
Cabozantinib in combination with atezolizumab in patients with mCRPC
Prof Neeraj Agarwal - University of Utah School of Medicine, Salt Lake CIty, US...
Cabozantinib in combination with atezolizumab in patients with mCRPC ( Prof Neeraj Agarwal -  University of Utah School of Medicine, Salt Lake CIty, USA )
18 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 2
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
18 Sep 2021
Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or local...
Prof Thomas Powles - Queen Mary University of London, London, UK
Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa ( Prof Thomas Powles - Queen Mary University of London, London, UK )
17 Sep 2021
ESMO President: What to watch for at ESMO 2021
Prof Solange Peters - ESMO President
ESMO President: What to watch for at ESMO 2021 ( Prof Solange Peters - ESMO President )
17 Sep 2021